Comparative Pharmacology
Head-to-head clinical analysis: FOSCARNET SODIUM versus SYLATRON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOSCARNET SODIUM versus SYLATRON.
FOSCARNET SODIUM vs SYLATRON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Foscarnet is an organic analog of inorganic pyrophosphate that selectively inhibits the DNA polymerase activity of herpesviruses, including cytomegalovirus (CMV) and herpes simplex virus (HSV), at the pyrophosphate binding site without requiring activation by thymidine kinase. It also inhibits HIV reverse transcriptase.
Peginterferon alfa-2b binds to type I interferon receptors, activating JAK-STAT signaling and inducing expression of antiviral, antiproliferative, and immunomodulatory proteins.
Induction: 60 mg/kg IV every 8 hours for 14–21 days, followed by maintenance: 90–120 mg/kg IV once daily. Infuse at no more than 1 mg/kg/min via central or peripheral line.
200 mcg/kg subcutaneously once weekly for 1 year in combination with oral ribavirin.
None Documented
None Documented
Terminal elimination half-life is approximately 48 hours (range 24-88 hours), reflecting prolonged intracellular retention; clinical context necessitates dose adjustment for renal impairment and monitoring of renal function.
Terminal elimination half-life is approximately 40 hours (range 27-60 hours) following subcutaneous administration. This prolonged half-life supports once-weekly dosing.
Primarily excreted unchanged by the kidney via glomerular filtration and tubular secretion; >80% of dose recovered in urine within 24 hours; minimal biliary or fecal excretion (<5%).
Renal clearance is the primary route of elimination for peginterferon alfa-2b. Approximately 30% of the dose is excreted unchanged in urine, with the remainder metabolized and excreted via bile/feces.
Category A/B
Category C
Antiviral
Interferon Antineoplastic/Antiviral